Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY accumulated deficit (Tax losses applied to a buyout)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5636)
•••
Comment by Noteableon Feb 20, 2024 8:07pm
119 Views
Post# 35889956

RE:RE:RE:RE:RE:RE:RE:ONCY accumulated deficit (Tax losses applied to a buyout)

RE:RE:RE:RE:RE:RE:RE:ONCY accumulated deficit (Tax losses applied to a buyout) In response and as posted beforehand for further comparision,  IOVA has an accumulated deficit of US$1.463 Bln that translated to an underlying tax off-set of US$5.95 per share. Through 2023 the trading range for IOVA stock in 2023 was between US$5.71 and US$7.98 per share, which reflected the underlying accumulated deficit off-set of US$5.95 per share. 
 
In 2022 IOVA traded between US19.09 and US$6.18. And in 2021 IOVA traded at a high of US$51.08
 
Such evidence confirms that ONCY's share price has been intentionally held down by those trader/broker players on this message board who trade through CIBC World Markets and Canaccord, and seem to respond to Canadafan's posts.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities